Mariona Riudavets

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

Andrea De Giglio, Laura Mezquita, Édouard Auclin et al. · Cancers · 2020 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Mariona Riudavets, Joaquín Mosquera, Rosario García‐Campelo et al. · Frontiers in Oncology · 2020 · 56 citations · Full text

Pharmacy, Immunology, Oncology +17

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

Mariona Riudavets, Édouard Auclin, Miguel Mosteiro et al. · European Journal of Cancer · 2022 · 53 citations · Full text

Medicine, Molecular Genetics, Oncology +13

Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

Mariona Riudavets, Pablo Maroto, Ivana Sullivan et al. · Journal of Clinical Oncology · 2018 · 32 citations

Pharmacy, Immunology, Oncology +17

Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study

Nicolas Epaillard, José Carlos Benítez, Teresa Gorría et al. · Lung Cancer · 2021 · 24 citations

Medicine, Immunology, Oncology +12